论文部分内容阅读
观察糖肾康对糖尿病肾病（ＤＮ）患者尿白细胞介素６（ＩＬ－６）的影响，探讨糖肾康对ＤＮ治疗的作用机制。治疗组４６例采用糖肾康和卡托普利联合治疗，对照组４４例单用卡托普利，两组其他治疗相同，治疗时间为３个月，观察治疗前后尿ＩＬ－６的变化。结果表明，治疗后尿ＩＬ－６显著下降，与治疗前比较Ｐ＜０．０１，与对照组治疗后比较Ｐ＜０．０５；同时血糖、血脂、血流动力学和肾功能明显改善。表明糖肾康通过改善血糖、血脂代谢及血流动力学和直接抑制ＩＬ－６功能及分泌，而达到保护肾脏，使尿ＩＬ－６产生减少的作用。
To observe the effect of Tangshenkang on urinary interleukin-6 (IL-6) in patients with diabetic nephropathy (DN) and to explore the mechanism of Tangshenkang on DN treatment. In the treatment group, 46 cases were treated with Tangsikang and captopril. In the control group, only captopril was used in 44 cases. The other groups were treated with the same treatment for 3 months. The changes of urinary IL-6 before and after treatment were observed. The results showed that after treatment, urinary IL-6 decreased significantly, compared with P<0.01 before treatment, and P<0.05 after treatment compared with the control group; meanwhile, blood glucose, blood lipids, hemodynamics and renal function improved significantly. It is shown that Tangshenkang can protect the kidney and reduce urinary IL-6 production by improving blood glucose, blood lipid metabolism and hemodynamics, and directly inhibiting IL-6 function and secretion.